At the time of writing, Voyager Therapeutics Inc [VYGR] stock is trading at $8.36, up 6.91%. An important factor to consider is whether the stock is rising or falling in short-term value. The VYGR shares have gain 10.44% over the last week, with a monthly amount drifted -15.64%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Voyager Therapeutics Inc [NASDAQ: VYGR] stock has seen the most recent analyst activity on March 26, 2024, when Guggenheim initiated its Buy rating and assigned the stock a price target of $22. Previously, H.C. Wainwright started tracking the stock with Buy rating on March 19, 2024, and set its price target to $30. On March 07, 2024, Citigroup initiated with a Buy rating and assigned a price target of $16 on the stock. Wells Fargo upgraded its rating to a Overweight but stick to its price target of $14 on January 02, 2024. Truist initiated its recommendation with a Buy and recommended $18 as its price target on May 10, 2023. Oppenheimer started tracking with a Outperform rating for this stock on March 10, 2023, and assigned it a price target of $14. In a note dated October 07, 2021, Robert W. Baird upgraded an Outperform rating on this stock and boosted its target price from $6 to $9.
For the past year, the stock price of Voyager Therapeutics Inc fluctuated between $6.06 and $14.34. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. Voyager Therapeutics Inc [NASDAQ: VYGR] shares were valued at $8.36 at the most recent close of the market. An investor can expect a potential return of 91.39% based on the average VYGR price forecast.
Analyzing the VYGR fundamentals
According to Voyager Therapeutics Inc [NASDAQ:VYGR], the company’s sales were 250.01M for trailing twelve months, which represents an 5910.39% jump. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.49%, Pretax Profit Margin comes in at 0.53%, and Net Profit Margin reading is 0.53%. To continue investigating profitability, this company’s Return on Assets is posted at 0.38, Equity is 0.64 and Total Capital is 0.43. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.92 points at the first support level, and at 7.48 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.68, and for the 2nd resistance point, it is at 9.00.
Voyager Therapeutics Inc [VYGR] reported earnings per share of $1.25 for its fiscal quarter that ended on 12/31/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.29/share, meaning a difference of $1.54 and a surprise factor of 531.00%. By comparison, the stated earnings for the previous quarter ended on 9/30/2023 were -$0.59 per share as compared to estimates of -$0.58 per share, a difference of -$0.01 representing a surprise of -1.70%.
Ratios To Look Out For
It is important to note that Voyager Therapeutics Inc [NASDAQ:VYGR] has a current ratio of 4.96. On the other hand, the Quick Ratio is 4.96, and the Cash Ratio is 1.07. Considering the valuation of this stock, the price to sales ratio is 1.82, the price to book ratio is 1.56 and price to earnings (TTM) ratio is 2.70.
Transactions by insiders
Recent insider trading involved Sandrock Alfred, President and CEO, that happened on Apr 02 ’24 when 12115.0 shares were sold. Chief Operating Officer, Swartz Robin completed a deal on Apr 02 ’24 to sell 1357.0 shares. Meanwhile, President and CEO Sandrock Alfred sold 13033.0 shares on Feb 21 ’24.
